The COVID-19 pandemic has had a profound impact on the best-selling pharmaceuticals, leading to shifts in the list with Pfizer and BioNTech’s Comirnaty surpassing AbbVie’s Humira for the No. 1 spot in 2021. That momentum continued in 2022, with Pfizer and BioNTech jointly raking in $59.1 billion in revenue from the sales of the COVID-19…
As COVID-19 threats to become endemic, a potential silver lining for pharma
Reality is beginning to sink in. Despite the availability of a growing number of COVID-19 vaccines and other therapies, the SARS-CoV-2 virus is likely to become endemic in the medium term, if not longer. A handful of coronaviruses — among them strains of NL63, OC43, 229E and HKU1 — are already endemic. For drug developers,…